Peptide Receptor Radionuclide Therapy (177Lu-DOTA Therapy) is a high-quality medication used to treat neuroendocrine tumours (NETs). Such tumours develop at such locations as the gut, the pancreas, the lungs, and the thymus, and may extend elsewhere in the body.  

It is administered as a regulated dosage that is approximately 100 mCi at a time. The use is done when it is unable to remove the cancer through surgery, it has spread, or is not responding well to other treatments.  

As opposed to the standard chemo or external radiation, 177Lu-DOTA treatment transmits radiation into the tumour cells with somatostatin receptors (SSTR) only. This treatment keeps healthy tissue relatively safe and enhances the treatment to perform better, particularly with well-differentiated and SSTR-positive NETs.  

What is 177Lu-DOTA Therapy?

The treatment involves a radioactive source, Lutetium-177, conjugated with a somatostatin-like medication:

• DOTA‑TATE  
• DOTA‑NOC  
• DOTA‑TOC  

These drugs target tumour cells with the SSTR. Once introduced into the bloodstream, the medicine is then transported to the cancer, binds to the receptors, and provides a local dose of beta radiation into the cancer. This destruction of the tumour DNA renders the growth of the cells impossible or kills them and causes the tumour to shrink or remain unchanged, sparing the adjacent healthy tissue.  

Indications for 177Lu-DOTA Therapy (PRRT)

The therapy is suggested for:

• Non-surgery-receptive or metastatic neuroendocrine tumours.  
• SSTR plus tumours that are confirmed with 68Ga -DOTA PET -CT scan.  
• NETs that recur and fail to respond to the normal forms of treatment.  
• Pancreatic, gastrointestinal, bronchial, and additional SSTR-positive NETs.  
• Patients whose illness continues despite the other interventions.  

It may reduce the progression of a disease, decrease the symptoms, and enhance quality of life.

Therapy Schedule and Dosage

• Usually given in 3 to 5 cycles  
• Cycles 6 -12 weeks.  
• Standard dose: 100 mCi per cycle

The precise course of action is determined by the health of a patient, the functionality of their kidneys and bone marrow, as well as the response of a tumour. Everything is done in a specialised nuclear medicine centre and is treated.  

Pre-Therapy Assessment

Patients receive pre-emergency:

• 68Ga -DOTA PET -CT scan to verify receptor existence.  
• Tests of kidney and liver functions.  
• Full blood count (CBC) to test bone-marrow reserve.  
• Detectable tumour markers (e.g., Chromogranin A)  
• Clinical examination and review of medication.  

PRRT is only administered to patients who qualify.  

Procedure of 177Lu-DOTA Therapy

The procedure is generally quite tolerable and involves:

• Admission of the patient and pre-medication (anti-nausea when necessary)  
• Amino-acid infusion was initiated before the treatment to provide kidney protection.  
• 177Lu -DOTA (100 mCi) IV slowly infused (30-60 min).  
• Vital signs observation during and after the infusion.  
• Compliance with the regulations of radiation safety.  

The patients are not hospitalised long, and most of them only spend up to 24 hours in the hospital.  

Post-Therapy Monitoring and Follow-Up

Patients are monitored by the following after every cycle:

• Kidney, liver, bone-marrow infections tests.  
• Tumour markers (e.g., Chromogranin A)  
• Follow-up (PET-CT or MRI) imaging.  
• Review of the symptoms (pain, appetite, fatigue)  
• Quality‑of‑life assessment  

The cycles will be scheduled in the future as per the response observed and the tolerance of the treatment by the patient.  

Benefits of 177Lu-DOTA Therapy

• Very targeted to SSTR cells  
• Buckling of the normal tissues is minimal.  
• Improved symptoms, like pains, flushing, and diarrhoea.  
• Slow tumour growth  
• Increased survivability of numerous patients.  
• Substitution of individuals unable to undergo chemo.  
• It is safe to repeat (to 45 cycles, in appropriate instances) 

Potential Side Effects

The treatment is largely unproblematic. Possible side effects are:

• Mild nausea or vomiting  
• Fatigue  
• Interim decline of blood cell lines (anemia, reduction in white cells, decrease in platelets)  
• Mild stomach discomfort  
• Dry mouth or a metallic taste  

Less common risks include:

• Reduced kidney functions (reduced by amino-acid infusion)  
• Bone‑marrow suppression  
• Rare liver toxicity  

Side effects are mostly temporary and should be dealt with through appropriate care. 

Who Should Avoid PRRT?

This treatment should not be applied to:

• Patients who have severe kidney or liver issues.  
• Poor bone‑marrow reserve  
• Carcinoma, which is SSTR negative (negative PET-CT).  
• pregnant women and lactating mothers.  

Eligibility will be determined following an extensive clinical assessment. 

Conclusion

177Lu-DOTA Therapy -100 mCi is a potent focused therapy for patients having advanced neuroendocrine tumours. It is a significant advancement in nuclear medicine by delivering the radiation directly to the cancer and sparing the normal tissues. The treatment manages tumour proliferation, enhances the quality of life of the eligible and is repeatable with no side effects.  

In case of neuroendocrine tumours, consult a nuclear medicine specialist or an oncologist on whether 177Lu -DOTA Therapy would be appropriate in your treatment.